Carisma voluntarily delisting from Nasdaq, terminating SEC reporting; appoints new CEO for wind-down

Carisma Therapeutics Inc.

Board approved voluntary delisting from Nasdaq; Form 25 expected Dec 10; delisting effective 10 days later.
Company to file Form 15 to suspend and terminate SEC reporting obligations under Sections 13 and 15(d).
Steven Kelly appointed interim CEO (consulting) at $350/hour through Dec 31, 2025.
Craig Jalbert to become CEO, President, Treasurer, Secretary and director Jan 1, 2026; $50K/year via his firm.
Three directors and VP Finance McAndrew resigning effective Dec 31, 2025; no disagreements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.